3347 — Hangzhou Tigermed Consulting Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeLarge CapHigh Flyer

Market Cap
HK$34.18bn
Enterprise Value
HK$38.13bn
Revenue
CNY6.60bn

Annual income statement for Hangzhou Tigermed Consulting Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	CAS	CAS	CAS	CAS	CAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	3,192	5,214	7,085	7,384	6,603
Cost of Revenue
Gross Profit	1,514	2,271	2,808	2,845	2,244
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	969	1,517	4,503	4,897	5,939
Operating Profit	2,223	3,697	2,582	2,487	664
Other Net Non Operating Costs
Net Income Before Taxes	2,219	3,685	2,585	2,489	664
Provision for Income Taxes
Net Income After Taxes	2,029	3,392	2,272	2,150	448
Minority Interest
Net Income Before Extraordinary Items
Net Income	1,750	2,874	2,007	2,025	405
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1,750	2,874	2,007	2,025	405
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.09	3.2	2.26	2.37	0.471
Dividends per Share